GlassScriptPhysician profile
Glenn A Bryant
NPI 1588686794
$2,314.79
in general payments reported to CMS, 2019-2025
30 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2021: $59.39 · 2022: $194 · 2023: $289 · 2024: $485 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123 · Education: $17.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.36 |
| Education | $17.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $403.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $275.65 | 2019-2025 | Airsupra, Farxiga |
| Vifor Pharma, INC. | $222.71 | 2019-2023 | Korsuva, Veltassa |
| Opko Pharmaceuticals, LLC | $157.33 | 2019-2024 | Rayaldee |
| Abbott Laboratories | $142.58 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $125.67 | 2019-2025 | Evenity |
| Novartis Pharmaceuticals Corporation | $109.03 | 2019-2024 | |
| Pfizer INC. | $85.61 | 2024-2025 | |
| Corcept Therapeutics | $83.32 | 2023 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.83 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $75.81 | 2024-2025 | Voquezna |
| Akebia Therapeutics INC | $59.78 | 2019 | |
| Alexion Pharmaceuticals, INC. | $58.37 | 2019-2022 | |
| Daiichi Sankyo INC. | $48.08 | 2019-2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $45.30 | 2019-2023 | Gattex |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $41.90 | 2019 | |
| Renalytix Ai, INC. | $40.10 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Mallinckrodt Enterprises LLC | $36.71 | 2019 | |
| Lilly USA, LLC | $33.01 | 2024 | Jardiance, Zepbound |
| Baxter Healthcare | $30.51 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $29.08 | 2019 | |
| Alvogen INC | $23.14 | 2025 | Teriparatide |
| Inspire Medical Systems, INC. | $20.83 | 2025 | Inspire |
| Nxstage Medical, INC. | $20.61 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.58 | 2023 | |
| Abbvie INC. | $15.42 | 2025 | |
| Axsome Therapeutics, INC. | $15.30 | 2023 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $11.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.22 | 2019 | |
| Travere Therapeutics, INC. | $1.66 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.